Frontiers in Clinical Drug Research - Anti-Allergy Agents: Volume 5


Book Description

Frontiers in Clinical Drug Research - Anti-Allergy Agents is a book series comprising of a selection of updated review articles relevant to the recent development of pharmacological agents used for the treatment of allergies. The scope of the reviews includes clinical trials of anti-inflammatory and anti-allergic drugs, drug delivery strategies used to treat specific allergies (such as inflammation, asthma and dermatological allergies), lifestyle dependent modes of therapies and the immunological or metabolic mechanisms that are of interest to researchers as targets for new drugs. The fifth volume of this series brings 5 reviews which cover the following topics: - Resistin: an irresistible therapeutic target for inflammatory diseases, allergy-related disorders, and cancer- Asthma in adults: evaluation, prevalence, and its clinical management- Nitrogen-containing heterocycles as anti-allergy agents- Experimental and clinical studies on the effects of nigella sativa and its constituents on allergic and immunological disorders- Aspirin desensitization/challenge in patients with cardiovascular diseases: current trends and advances Frontiers in Clinical Drug Research - Anti-Allergy Agents will be of interest to immunologists and drug discovery researchers interested in anti-allergic drug therapy as the series provides relevant cutting edge reviews written by experts in this rapidly expanding field




Frontiers in Clinical Drug Research – Anti Allergy Agents


Book Description

Frontiers in Clinical Drug Research - Anti-Allergy Agents is an exciting eBook series comprising a selection of updated review articles relevant to the recent development of pharmacological agents used for the treatment of allergies. The scope of the reviews includes clinical trials of anti-inflammatory and anti-allergic drugs, drug delivery strategies used to treat specific allergies (such as inflammation, asthma and dermatological allergies), lifestyle dependent modes of therapies and the immunological or metabolic mechanisms that are of interest to researchers as targets for new drugs. The second volume of this series brings 7 reviews which cover neuro- and immunomodulating therapies for asthma and COPD, antioxidant therapies for allergies, allergic rhinitis medications and more. Frontiers in Clinical Drug Research - Anti-Allergy Agents will be of interest to immunologists and drug discovery researchers interested in anti-allergic drug therapy as the series provides relevant cutting edge reviews written by experts in this rapidly expanding field.




Frontiers in Clinical Drug Research - Anti-Allergy Agents: Volume 4


Book Description

Frontiers in Clinical Drug Research - Anti-Allergy Agents is a book series comprising of a selection of updated review articles relevant to the recent development of pharmacological agents used for the treatment of allergies. The scope of the reviews includes clinical trials of anti-inflammatory and anti-allergic drugs, drug delivery strategies used to treat specific allergies (such as inflammation, asthma and dermatological allergies), lifestyle dependent modes of therapies and the immunological or metabolic mechanisms that are of interest to researchers as targets for new drugs. The fourth volume of this series brings 5 reviews which cover the following topics: Anti-inflammatory and Immunomodulatory properties of medicinal plant products Helminth therapy: a new tool for treatment of allergic diseases An overview of anti-allergic medications in paediatric population In-silico approaches in drug discovery and design of anti-allergic agents Microbiota and allergy: possible Interventions Frontiers in Clinical Drug Research - Anti-Allergy Agents will be of interest to immunologists and drug discovery researchers interested in anti-allergic drug therapy as the series provides relevant cutting edge reviews written by experts in this rapidly expanding field.




Frontiers in Clinical Drug Research - Anti-Allergy Agents


Book Description

Frontiers in Clinical Drug Research - Anti-Allergy Agents is an exciting eBook series comprising a selection of updated review articles relevant to the recent development of pharmacological agents used for the treatment of allergies. The scope of the reviews includes clinical trials of anti-inflammatory and anti-allergic drugs, drug delivery strategies used to treat specific allergies (such as inflammation, asthma and dermatological allergies), lifestyle dependent modes of therapies and the immunological or metabolic mechanisms that are of interest to researchers as targets for new drugs. The second volume of this series brings 7 reviews which cover neuro- and immunomodulating therapies for asthma and COPD, antioxidant therapies for allergies, allergic rhinitis medications and more. Frontiers in Clinical Drug Research - Anti-Allergy Agents will be of interest to immunologists and drug discovery researchers interested in anti-allergic drug therapy as the series provides relevant cutting edge reviews written by experts in this rapidly expanding field.




Frontiers in Clinical Drug Research - Anti-Allergy Agents


Book Description

Frontiers in Clinical Drug Research - Anti-Allergy Agents is a book series comprising of a selection of updated review articles relevant to the recent development of pharmacological agents used for the treatment of allergies. The scope of the reviews includes clinical trials of anti-inflammatory and anti-allergic drugs, drug delivery strategies used to treat specific allergies (such as inflammation, asthma and dermatological allergies), lifestyle dependent modes of therapies and the immunological or metabolic mechanisms that are of interest to researchers as targets for new drugs. The third volume of this series brings 5 reviews which cover the following topics: H1 receptor selectivity, chronic spontaneous urticaria therapy, smooth muscle cell Ca2+ signaling pathway targeting for asthma therapy, allergic rhinitis and endosomal toll-like receptors. Frontiers in Clinical Drug Research - Anti-Allergy Agents will be of interest to immunologists and drug discovery researchers interested in anti-allergic drug therapy as the series provides relevant cutting edge reviews written by experts in this rapidly expanding field.




Frontiers in Clinical Drug Research - Anti-Allergy Agents


Book Description

Frontiers in Clinical Drug Research - Anti-Allergy Agents is an exciting eBook series comprising a selection of updated review articles relevant to the recent development of pharmacological agents used for the treatment of allergies. The scope of the revi




Frontiers in Clinical Drug Research – Anti Allergy Agents


Book Description

Frontiers in Clinical Drug Research - Anti-Allergy Agents is an exciting eBook series comprising a selection of updated review articles relevant to the recent development of pharmacological agents used for the treatment of allergies. The scope of the reviews includes clinical trials of anti-inflammatory and anti-allergic drugs, drug delivery strategies used to treat specific allergies (such as inflammation, asthma and dermatological allergies), lifestyle dependent modes of therapies and the immunological or metabolic mechanisms that are of interest to researchers as targets for new drugs. The first volume of this series sheds light on new therapies that can be employed for allergic reactions in patients (both traditional and non-traditional therapies), nutrition based therapies and the use of substances such as omalizumab and adrenaline to counter inflammatory response and anaphylaxis in patients. Frontiers in Clinical Drug Research - Anti-Allergy Agents will be of interest to immunologists and drug discovery researchers interested in anti-allergic drug therapy as the series provides relevant cutting edge reviews written by experts in this rapidly expanding field.




Frontiers in Clinical Drug Research - CNS and Neurological Disorders: Volume 9


Book Description

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology. The ninth volume of this series features reviews that cover the following topics related to the treatment of a different CNS disorders, related diseases and basic neuropharmacology research: - Integrating imaging and microdialysis into systems neuropharmacology - Depression heterogeneity and the potential of a transdiagnostic and dimensional approach to identify biologically relevant phenotypes - CAR-T cells in brain tumors and autoimmune diseases – from basics to the clinic - Revaluation of thyrotropin-releasing hormone and its mimetics as candidates for treating a wide range of neurological and psychiatric disorders - Natural BACE1 inhibitors: promising drugs for the management of Alzheimer’s disease - The possibilities of safe lithium therapy in the treatment of neurological and psychoemotional disorders - Pharmacotherapy of multiple sclerosis and treatment strategies




Communities in Action


Book Description

In the United States, some populations suffer from far greater disparities in health than others. Those disparities are caused not only by fundamental differences in health status across segments of the population, but also because of inequities in factors that impact health status, so-called determinants of health. Only part of an individual's health status depends on his or her behavior and choice; community-wide problems like poverty, unemployment, poor education, inadequate housing, poor public transportation, interpersonal violence, and decaying neighborhoods also contribute to health inequities, as well as the historic and ongoing interplay of structures, policies, and norms that shape lives. When these factors are not optimal in a community, it does not mean they are intractable: such inequities can be mitigated by social policies that can shape health in powerful ways. Communities in Action: Pathways to Health Equity seeks to delineate the causes of and the solutions to health inequities in the United States. This report focuses on what communities can do to promote health equity, what actions are needed by the many and varied stakeholders that are part of communities or support them, as well as the root causes and structural barriers that need to be overcome.




Antiprotozoal Drug Discovery: A Challenge That Remains


Book Description

Protozoan infections that are endemic in countries with limited economic resources pose a significant public health challenge to affected communities and some of these diseases are categorized as neglected tropical diseases by the World Health Organization. At the moment, there is an urgent need to identify and develop new antiprotozoal drugs. Antiprotozoal Drug Discovery: A Challenge That Remains brings together research from all scientists (including parasitologists, chemists, biologists among others) involved in the field of antiprotozoal experimental pharmacology, drug design and natural product research. The monograph is a compilation of review chapters written by experts on medical parasitology and pharmacology that covers a wide range of topics such as general characteristics of protozoan diseases (malaria, toxoplasmosis, Chagas’ disease, leishmaniasis, trichomoniasis) prophylaxis, treatments, natural products and rational drug design. The contents of this book are useful to medical microbiologists and pharmaceutical scientists seeking to update their knowledge about antiprotozoal drug design.